Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA).

Address: a Department of Cardiology , Oslo University Hospital Rikshospitalet , Oslo , Norway.; b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway.; c K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research , University of Oslo , Oslo , Norway.; d Faculty of Medicine , University of Oslo , Oslo , Norway.; e Department of Cardiology , Hull York Medical School, University of Hull, Castle Hill Hospital , Kingston-upon-Hull, Glasgow , UK.; f British Heart Foundation Glasgow Cardiovascular Research Centre , University of Glasgow , Glasgow , UK.; g Sahlgrenska University Hospital , Gøteborg , Sweden.; h K.G. Jebsen Inflammatory Research Center , University of Oslo , Oslo , Norway.; i Section of Clinical Immunology and Infectious Diseases , Oslo University Hospital Rikshospitalet Oslo , Norway.; j K.G. Jebsen Thrombosis Research and Expertise Center , University of Tromsø , Tromsø , Norway.